Market Introduction
Hemostasis analyzers are devices that measure clotting mechanisms of hemostasis to detect clotting deficiencies and facilitate the treatment of patients with an excess bleeding condition by medical practitioners. Constant technical advancement has led to the launch of many innovative drugs, and instruments such as high-performance hemostasis analyzers are projected to fuel demand growth for hemostasis analyzers.
The report provides trends prevailing in the Asia Pacific hemostasis analyzers market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to rising number of cardiovascular diseases and rise in the geriatric population are the key factors driving the market growth. However, the market is expected to experience slow growth during the forecast period owing to high cost of fully automated hemostasis analyzer.
The socio-economics were severely affected, rising in negative inflation, GDPs, and a regional unemployment surge. Recently, patients with both hypertension and obesity have been increasing in Japan. These patients are at exceptionally high risk for severe disease in COVID-19 and thus need careful observation and intensive treatment. Comparable to hypertension, the definition of obesity is not constant among studies/countries, which requires consideration. However, it is essential to note that the therapeutic mechanism of CCB against COVID-19 still awaits further investigation and randomized controlled clinical trials.The pandemic has affected three main aspects of the global economy: production, supply chain, and firms and financial markets. Japan, China, South Korea, India, and Australia are the most affected countries due to the increasing number of COVID-19 cases and the associated deaths. This scenario positively impacts the hemostasis analyzers. This pandemic is affecting the business operation of the various key players operating in this region.
Market Overview and Dynamics
The Asia Pacific hemostasis analyzers market in the Asia Pacific is expected to grow from US$ 736.69 million in 2021 to US$ 1,424.59 million by 2028; it is estimated to grow at a CAGR of 9.9% from 2021 to 2028. Hemostasis analyzers provide a quick and easy measurement of blood platelet levels. A coagulation test could help detect and prevent blood clots that could cause a heart attack. A coagulation analyzer can measure the speed of the coagulation pathway and the amounts of thrombolin and thromboplastin in less than a few minutes.
Cardiovascular diseases (CVDs) are likely to remain the most significant cause of morbidity and mortality worldwide. The CVDs are disorders of the heart and blood vessels and include cerebrovascular disease, coronary heart disease, rheumatic heart disease, and other conditions. Some lifestyle-related issues that lead to cardiovascular diseases and difficulties are tobacco use, unhealthy diet, and physical inactivity. They increase the risk of heart attacks and strokes. Other risk factors for cardiovascular diseases are high blood pressure, diabetes, and increased cholesterol levels. According to the WHO, cardiovascular diseases are the number one cause of death. Moreover, the growing awareness regarding the benefits of hemostasis analyzers, such as reducing conduction in atrioventricular nodes, in controlling atrial fibrillation patients' heart rate is adding to their demands, aiding the market.
In terms of product type, the laboratory analyzer segment accounted for the largest share of the Asia Pacific hemostasis analyzers market in 2020. In terms of test, the d-dimer test segment accounted for the largest share of the Asia Pacific hemostasis analyzers market in 2020. In terms of end user, the hospital/clinics segment accounted for the largest share of the Asia Pacific hemostasis analyzers market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the Asia Pacific hemostasis analyzers market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical databases, among others. Major companies listed in the report are Siemens Healthineers AG , Abbott , Sysmex Corporation , Nihon Kohden Corporation ,THERMO FISHER SCIENTIFIC INC. ,HOFFMANN-LA ROCHE LTD. , Instrumentation Laboratory Company.
Reasons to buy report
Asia Pacific Hemostasis Analyzers Market Segmentation
By Product Type
By Test
By Country
Companies Mentioned -
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 736.69 Million |
| Market Size by 2028 | US$ 1,424.59 Million |
| CAGR (2021 - 2028) | 9.9% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Hemostasis Analyzers Market is valued at US$ 736.69 Million in 2021, it is projected to reach US$ 1,424.59 Million by 2028.
As per our report Asia Pacific Hemostasis Analyzers Market, the market size is valued at US$ 736.69 Million in 2021, projecting it to reach US$ 1,424.59 Million by 2028. This translates to a CAGR of approximately 9.9% during the forecast period.
The Asia Pacific Hemostasis Analyzers Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Hemostasis Analyzers Market report:
The Asia Pacific Hemostasis Analyzers Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Hemostasis Analyzers Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Hemostasis Analyzers Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)